Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation.

AIMS The aim of this study was to report medium-term outcomes of MitraClip implantation in inoperable or high-risk surgical candidates with functional mitral regurgitation (FMR) in our single-centre experience. From October 2008, 109 consecutive patients with FMR underwent MitraClip implantation (mean age 69±9 years; 82% NYHA Class III-IV). Logistic EuroSCORE was 22±16%. Comorbidities included: chronic renal failure (47%), diabetes (22%), COPD (28%). Mean EF was 28±11%; LVEDD was 68±8 mm. Procedural success was 99% and 30-day mortality was 1.8%. At discharge, 87% patients had MR ≤2+. At 12 months, EF was 34.7±10.4% (p=0.002 compared to preoperative value). Actuarial survival at three years was 74.5±7%. Actuarial freedom from MR ≥3+ at 2.5 years was 70±6%. At one-year follow-up, 86% of patients were in NYHA Class I-II. Preoperative pro-BNP level ≥1,600 pg/ml was identified as an independent risk factor of mortality at follow-up. MitraClip therapy for FMR is a valuable alternative to surgery in high-risk patients. Higher preoperative pro-BNP level is a risk factor for mortality at follow-up. Although patients treated in current practice are high-risk, the procedure remains safe and effective in selected patients.

[1]  Hani N Sabbah,et al.  Mitral valve surgery in heart failure: insights from the Acorn Clinical Trial. , 2006, The Journal of thoracic and cardiovascular surgery.

[2]  S. Blankenberg,et al.  Aetiology of mitral regurgitation differentially affects 2‐year adverse outcomes after MitraClip therapy in high‐risk patients , 2013, European journal of heart failure.

[3]  Scott Lim,et al.  Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. , 2009, Journal of the American College of Cardiology.

[4]  Yong-Jin Kim,et al.  Prognostic value of B-type natriuretic peptide in patients with chronic mitral regurgitation undergoing surgery: mid-term follow-up results. , 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[5]  Saibal Kar,et al.  Percutaneous repair or surgery for mitral regurgitation. , 2011, The New England journal of medicine.

[6]  O. Alfieri,et al.  Mitral Valve Repair for Functional Mitral Regurgitation in End-Stage Dilated Cardiomyopathy: Role of the “Edge-to-Edge” Technique , 2005, Circulation.

[7]  M. Pfisterer,et al.  Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. , 2004, The New England journal of medicine.

[8]  O. Alfieri,et al.  Recurrence of mitral regurgitation parallels the absence of left ventricular reverse remodeling after mitral repair in advanced dilated cardiomyopathy. , 2008, The Annals of thoracic surgery.

[9]  Nader Moazami,et al.  Recurrent mitral regurgitation and risk factors for early and late mortality after mitral valve repair for functional ischemic mitral regurgitation. , 2008, The Annals of thoracic surgery.

[10]  S. Bolling,et al.  Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. , 2005, Journal of the American College of Cardiology.

[11]  C. Tamburino,et al.  Left cardiac chambers reverse remodeling after percutaneous mitral valve repair with the MitraClip system. , 2012, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[12]  O. Alfieri,et al.  The double-orifice technique in mitral valve repair: a simple solution for complex problems. , 2001, The Journal of thoracic and cardiovascular surgery.

[13]  J. Hausleiter,et al.  Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. , 2013, Journal of the American College of Cardiology.

[14]  J B Seward,et al.  Determinants of the Degree of Functional Mitral Regurgitation in Patients With Systolic Left Ventricular Dysfunction: A Quantitative Clinical Study , 2000, Circulation.

[15]  Jeroen J. Bax,et al.  Restrictive Annuloplasty and Coronary Revascularization in Ischemic Mitral Regurgitation Results in Reverse Left Ventricular Remodeling , 2004, Circulation.

[16]  P. Boekstegers,et al.  Acute outcomes after MitraClip therapy in highly aged patients: results from the German TRAnscatheter Mitral valve Interventions (TRAMI) Registry. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[17]  O. Alfieri,et al.  Percutaneous mitral valve repair with the edge-to-edge technique. , 2010, Multimedia manual of cardiothoracic surgery : MMCTS.

[18]  W. Rottbauer,et al.  Acute safety and 30-day outcome after percutaneous edge-to-edge repair of mitral regurgitation in very high-risk patients. , 2011, The American journal of cardiology.

[19]  O. Alfieri,et al.  Guidelines on the management of valvular heart disease. , 2007, European heart journal.

[20]  C. O'connor,et al.  Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. , 2003, The American journal of cardiology.

[21]  Jeroen J. Bax,et al.  Preoperative left ventricular dimensions predict reverse remodeling following restrictive mitral annuloplasty in ischemic mitral regurgitation. , 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[22]  Gabriel Thabut,et al.  Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. , 2004, Journal of the American College of Cardiology.

[23]  S. Bolling,et al.  Early improvement in congestive heart failure after correction of secondary mitral regurgitation in end-stage cardiomyopathy. , 1995, American heart journal.

[24]  Ischemic Mitral Regurgitation Long-Term Outcome and Prognostic Implications With Quantitative Doppler Assessment , 2001 .

[25]  John A Kellum,et al.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury , 2007, Critical care.

[26]  Philippe Ravaud,et al.  What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? , 2007, European heart journal.

[27]  C. Nienaber,et al.  Residual mitral valve regurgitation after percutaneous mitral valve repair with the mitraclip® system is a risk factor for adverse one‐year outcome , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[28]  T. Meinertz,et al.  MitraClip® therapy in patients with end‐stage systolic heart failure , 2011, European journal of heart failure.

[29]  S. Bolling,et al.  Early outcome of mitral valve reconstruction in patients with end-stage cardiomyopathy. , 1995, The Journal of thoracic and cardiovascular surgery.

[30]  O. Alfieri,et al.  Guidelines on the management of valvular heart disease (version 2012). , 2012, European heart journal.

[31]  O. Alfieri,et al.  The GeoForm annuloplasty ring for the surgical treatment of functional mitral regurgitation in advanced dilated cardiomyopathy. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[32]  M. Neuss,et al.  Patient selection criteria and midterm clinical outcome for MitraClip therapy in patients with severe mitral regurgitation and severe congestive heart failure , 2013, European journal of heart failure.